Compare Amylx Pharmaceuticals Inc (AMLX) vs Commvault Systems Inc (CVLT) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Commvault (CVLT) trades at $150.57, down 0.57% on the day, with a bullish technical signal from moving averages and strong support at $146. The company reported revenue of $995.62M in 2025, with net income of $76.11M, though earnings have been mixed with two beats and one miss in recent quarters. A high P/E of 95.3 indicates premium valuation, while ROE stands at 42.49%. Recent news highlights a securities class action lawsuit with a July 17, 2026 deadline.

Outlook is mixed: analyst consensus is bullish with 54.55% buy ratings and a $128.75 price target, but legal risks and high valuation pose headwinds. Revenue growth to $1.2B in 2026 offers upside, yet profit margin compression and lawsuit uncertainty require caution for investors seeking stability.